Resistant CMV After Transplant: Foscarnet or Maribavir
A single patient, on his third week of valganciclovir with a rising, not falling, CMV viral load and a genotype that explains why. The disagreement is between a drug proven to clear resistant virus and a drug that avoids the exact organ injury he can least afford right now.
C.M., a 52-year-old former commercial pilot grounded by the pulmonary fibrosis that eventually took both lungs, received a bilateral lung transplant four months ago and has been slowly rebuilding the stamina to walk his neighborhood block without stopping. He developed CMV viremia six weeks post-transplant, unsurprising in a lung recipient given how CMV-permissive transplanted lung tissue is, and started standard-dose valganciclovir. Three weeks in, his viral load hasn't fallen — it's risen, nearly tenfold from where it started — despite confirmed medication adherence and no absorption concerns. Genotypic resistance testing sent when the trend became unmistakable has come back positive for a UL97 mutation, the gene most commonly responsible for ganciclovir and valganciclovir resistance, confirming that the rising numbers reflect a truly resistant virus, not a dosing or adherence problem.
His creatinine has also crept upward over these same three weeks, from a stable post-transplant baseline of 1.0 to 1.4 mg/dL, attributed for now to his calcineurin-inhibitor regimen rather than anything CMV-related. That renal trajectory is the fact hanging over both options in front of the team. Foscarnet, a pyrophosphate analog that inhibits CMV DNA polymerase without requiring viral kinase activation — which is exactly why it retains activity against UL97-mutant virus — has well-documented, dose-limiting nephrotoxicity of its own, on top of a kidney already trending the wrong direction. Maribavir, which inhibits the same UL97 kinase the resistance mutation has altered rather than depending on it, showed superior viral clearance and meaningfully better tolerability than investigator-assigned therapy (foscarnet included) in the SOLSTICE trial — but SOLSTICE's own population was refractory or resistant CMV broadly, not renal function specifically, and maribavir's real advantage here may be less about its resistance profile and more about what it doesn't do to a kidney that's already under strain. One further mechanistic wrinkle bears directly on how the drugs would be sequenced, not just chosen: maribavir inhibits the same UL97 kinase that ganciclovir and valganciclovir require for their own activation, which means the two are pharmacologically antagonistic and cannot be run together — whichever option the team lands on, his valganciclovir needs to stop outright, not taper alongside a new drug the way some other switches allow.
Transplant ID rounds, week three
I'd switch him to maribavir. SOLSTICE showed superior viral clearance and better tolerability than investigator-assigned therapy — foscarnet included — for refractory or resistant CMV, and mechanistically it inhibits the same UL97 kinase his mutation has altered, rather than simply working around it the way a non-kinase-dependent drug does. That's a more targeted fit for the specific resistance he has.
If his resistance were UL54-mediated instead of UL97, this argument would change substantially — maribavir's target relationship to his specific mutation is a real part of why I'm reaching for it here.
I'd lean toward foscarnet, mostly on how much longer it's been used specifically against UL97-mutant CMV. SOLSTICE's population was broader refractory/resistant disease, not confirmed UL97 genotype alone, and I'd want a bit more genotype-specific confidence before moving away from the option with the deepest track record here — even knowing foscarnet's nephrotoxicity is a real cost in a patient whose creatinine is already climbing.
I'm not disputing the mechanistic argument for maribavir — I'm saying a trial result in a broader population isn't quite the same evidentiary weight as years of experience against his exact resistance mechanism, even if the newer drug's logic is sound.
I'd move to maribavir, and I want to make the actual deciding factor explicit: his creatinine has already risen from 1.0 to 1.4 over these three weeks on tacrolimus alone. Foscarnet's dose-limiting nephrotoxicity added on top of that isn't a background risk — in a bilateral lung transplant recipient who cannot afford a renal complication right now, compounding two nephrotoxic processes is a real, specific harm, not a theoretical one.
I take the nephrologist's point that maribavir's trial data aren't genotype-matched with certainty — but the renal-sparing argument doesn't depend on that match being perfect, only on foscarnet's own toxicity being as well-established as it is.
Agreed: maribavir started today, valganciclovir discontinued, with CMV viral load rechecked weekly and renal function monitored alongside it now that the nephrotoxic alternative has been avoided.
Not fully settled: the nephrologist's preference for a genotype-matched track record over a broader trial population remains a fair standing concern, and the team agreed explicitly that if maribavir fails to bring the viral load down within two weeks, foscarnet returns to the table — renal trajectory notwithstanding — rather than being treated as permanently ruled out.